Overview Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis Status: RECRUITING Trial end date: 2026-07-01 Target enrollment: Participant gender: Summary This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.Phase: PHASE2 Details Lead Sponsor: NS Pharma, Inc.Collaborator: Nippon Shinyaku Co., Ltd.